纳武利尤单抗联合伊匹木单抗治疗潜在可切除肝细胞癌的长期疗效与生物标志物探索
本研究评估纳武利尤单抗联合伊匹木单抗在潜在可切除肝细胞癌患者中的疗效与安全性,并探索预测治疗反应的生物标志物。43例患者接受纳武利尤单抗(3 mg/kg)联合伊匹木单抗(1 mg/kg)每3周治疗,24例接受手术,8例达到主要病理缓解(>90%肿瘤坏死)。估计4年无进展生存率和总生存率分别为44%(95%CI 28-59%)和60%(95%CI 42-74%),干扰素-γ和三级淋巴结构特征与客观反应相关。
要点
- 新辅助纳武利尤单抗联合伊匹木单抗后手术在潜在可切除肝细胞癌中可行,可能改善长期生存。
- 免疫治疗诱导的三级淋巴结构形成与增强的抗肿瘤免疫相关。
- 外周血T细胞耗竭监测可能有助于预测免疫治疗反应。
核心结论
- 新辅助纳武利尤单抗联合伊匹木单抗后手术在潜在可切除肝细胞癌中可行,可能改善长期生存。
- 免疫治疗诱导的三级淋巴结构形成与增强的抗肿瘤免疫相关。
研究设计与样本
- 单臂临床试验,纳入43例潜在可切除肝细胞癌患者(男/女:37/6;病毒性/非病毒性:41/2;BCLC分期A/B/C:4/13/26;中位肿瘤大小8.7 cm)。
- 患者接受纳武利尤单抗(3 mg/kg)联合伊匹木单抗(1 mg/kg)每3周治疗,2和4周期后评估肿瘤反应,然后根据临床指南进行根治性手术或替代治疗。
- 收集连续肿瘤和外周血样本进行基因组、转录组分析和免疫细胞谱分析。
主要发现
- 43例患者中24例接受手术,8例达到主要病理缓解(>90%肿瘤坏死)。
- 估计4年无进展生存率为44%(95%CI 28-59%),总生存率为60%(95%CI 42-74%)。
- 切除肿瘤中干扰素-γ和三级淋巴结构特征增加与客观反应相关。
- 小鼠肝癌模型中B细胞耗竭消除了抗PD-1联合抗CTLA-4治疗的疗效,支持三级淋巴结构的机制作用。
- 基线和免疫治疗后外周血T细胞活化和耗竭(通过光谱流式细胞术和深度学习算法评估)与反应和生存相关。
临床怎么用
- 对于潜在可切除肝细胞癌患者,可考虑新辅助纳武利尤单抗联合伊匹木单抗治疗后手术。
- 监测外周血T细胞耗竭可能有助于预测免疫治疗反应。
局限性
- 单臂临床试验设计,缺乏随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Immune checkpoint inhibitor-based combination therapy has demonstrated high objective response rates in patients with hepatocellular carcinoma (HCC) and may improve clinical outcomes as neoadjuvant or perioperative therapy. This study evaluated the efficacy and safety of nivolumab plus ipilimumab in patients with potentially resectable HCC and explored predictive biomarkers of treatment response. METHODS: Eligible patients received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks. Tumor response was assessed after two and four treatment cycles. Patients then proceeded to curative surgery or alternative treatments according to clinical guidelines. Serial tumor and peripheral blood samples were collected for genomic and transcriptomic analyses and immune cell profiling. RESULTS: Among the 43 enrolled patients (men/women: 37/6; viral/non-viral: 41/2; Barcelona Clinic Liver Cancer stage A/B/C: 4/13/26; median tumor size: 8.7 cm), 24 underwent surgery, and eight achieved a major pathological response (>90% tumor necrosis). The estimated 4-year progression-free survival and overall survival rates were 44% (95% CI 28-59%) and 60% (95% CI 42-74%), respectively. Increased interferon-γ and tertiary lymphoid structure (TLS) signatures in resected tumors were associated with objective response. In a mouse liver cancer model, B-cell depletion abolished the efficacy of anti-programmed death-1 plus anti-cytotoxic T lymphocyte-associated protein 4 therapy, supporting the mechanistic role of TLS. Peripheral blood T-cell activation and exhaustion at baseline and post-immunotherapy, assessed using spectral flow cytometry and deep learning algorithms, correlated with response and survival. CONCLUSIONS: Neoadjuvant nivolumab plus ipilimumab followed by surgery is feasible and may improve long-term survival in patients with potentially resectable HCC. Immunotherapy-induced TLS formation is associated with enhanced antitumor immunity. IMPACT AND IMPLICATIONS: Immune checkpoint inhibitor-based systemic therapy is now an integral component of the multidisciplinary management of patients with hepatocellular carcinoma. Findings from this single-arm clinical trial indicate that: i) neoadjuvant nivolumab plus ipilimumab followed by surgery is feasible and may improve long-term survival in patients with potentially resectable hepatocellular carcinoma; ii) immunotherapy-induced tertiary lymphoid structure formation is associated with enhanced antitumor immunity; iii) monitoring T-cell exhaustion in peripheral blood may aid in the prediction of response to immunotherapy. CLINICAL TRIAL NUMBER: NCT03510871.
引用
- Lin YJ, Ou DL, Su YY, et al. Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration. J Hepatol. 2025. PMID: 40972843. doi:10.1016/j.jhep.2025.08.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。